CAC 40: the market returns above 8,100 points

The CAC40 is moving into positive territory this midday, returning above 8,100 points to 8,115 points (+0.30%). The trend remains driven by the expectation of further progress on the Iranian issue. According to a high-level source cited by Reuters, no agreement has yet been formalized with Washington, even if the gaps between positions are narrowing. American Secretary of State Marco Rubio also spoke of signs of improvement in trade.

On the bond market, pressure remains high on American rates, still close to their highest levels since 2007 at maturity at 30 years. The latest minutes from the American central bank also confirm a more restrictive orientation, with a growing proportion of officials in favor of raising rates, which fuels the idea of ​​a less accommodating monetary cycle than expected.

On the macroeconomic level, Germany confirms GDP growth of 0.3% in the first quarter of 2026, in line with the first estimate. This progression is identical to that of the previous quarter, which reflects a still moderate dynamic of the largest economy in the euro zone.

In the United States, the afternoon agenda will be dominated by the Conference Board’s index of leading indicators as well as the final consumer confidence index from the University of Michigan.

The euro/dollar parity stands at around $1.16 at midday. Brent is trading at $106, while gold is trading at $4,515 per ounce.

Values

Nanobiotix grew by 11%, followed by Maat Pharma (+10%) which rebounded after its recent sharp decline, as well as Ubisoft and OSE.

Parrot gained 9%, accompanied by Ekinops (+6%), Atos (+5%) and Soitec.

X-Fab advances 3.5%, in a movement shared with Vusion, STMicroelectronics, Exail and Inventiva.

Compagnie des Alpes grew by 3.5%. The group published a half-year turnover of €883 million, up 3.9% year-on-year and 3.1% on a comparable basis. EBITDA reached €328 million, up 5%, with a margin rate of 37.1%. The group’s net profit came to €145 million, up 7.7%.

Genfit gains 2.5%. The company has cash of €136.1 million as of March 31, 2026, compared to €129.5 million a year earlier. It benefited in particular from a milestone of €17 million linked to its partnership with Ipsen and from a payment of €30 million as part of a royalty financing agreement. Quarterly turnover reached €9.6 million compared to €2.8 million a year earlier.

Forvia grew by 2.5%, supported in particular by Exosens and Verallia.

Stellantis advances by 2.2%. The group detailed its objectives for 2030 in its FaSTLAne plan, targeting €190 billion in revenue, an operating margin of 7%, positive industrial free cash flow in 2027 and €6 billion in 2030, as well as a cost reduction of 6 billion by 2028.

Falling values

Innate Pharma fell 10%, followed by Viel (-3%) and Poxel (-2.5%).

Elior loses 2%. The group adjusted its annual objectives after the publication of a warning, with organic growth expected between 1% and 2% compared to 3% to 4% previously, an EBITA margin around 3% and debt leverage close to 3.5x. Several analysis offices have revised their objectives.

Eutelsat lost 1.5%, along with SES.

Guerbet fell by 1%, as did M&P, TotalEnergies, North Atlantic and Kering.

Medincell lost 1%, despite the acceptance by the EMA of the marketing authorization application file for its TEV-749 treatment developed with Teva.